Enterprise Value

1.354B

Cash

405.9M

Avg Qtr Burn

-60.02M

Short % of Float

13.99%

Insider Ownership

6.80%

Institutional Own.

88.93%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
REC-2282 Details
Neurofibromatosis Type 2-mutated meningiomas

Phase 2/3

Data readout

REC-4881 Details
Familial Adenomatous Polyposis

Phase 2

Data readout

REC-994 Details
Cerebral cavernous malformation

Phase 2

Data readout

REC-3964 Details
Clostridium difficile Colitis

Phase 2

Initiation

Phase 2

Initiation

REC-3599 Details
GM2 gangliosidosis

Failed

Discontinued